Dr. Sartor on Mechanism of Action and Safety of Radium-223 in mCRPC

Oliver Sartor, MD
Published: Tuesday, Jun 21, 2016



Oliver Sartor, MD, medical director of Tulane Cancer Center, discusses the mechanism of action of radium-223 dichloride (Xofigo) as well as its safety profile for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Radium-223 has a unique mechanism of action in that it binds to hydroxyapatite and radiates the tumor microenvironment. Though the mechanism of action is not yet fully understood by researchers, Sartor says it could have pro-immune effect, anti-angiogenic effect, and/or a microenvironmental effect on tumors. 

Grade 3/4 thrombocytopenia is one treatment-related adverse event associated with radium-223. Less common and lower grade adverse events include anemia, leukopenia, diarrhea, and fatigue, he says.
SELECTED
LANGUAGE


Oliver Sartor, MD, medical director of Tulane Cancer Center, discusses the mechanism of action of radium-223 dichloride (Xofigo) as well as its safety profile for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Radium-223 has a unique mechanism of action in that it binds to hydroxyapatite and radiates the tumor microenvironment. Though the mechanism of action is not yet fully understood by researchers, Sartor says it could have pro-immune effect, anti-angiogenic effect, and/or a microenvironmental effect on tumors. 

Grade 3/4 thrombocytopenia is one treatment-related adverse event associated with radium-223. Less common and lower grade adverse events include anemia, leukopenia, diarrhea, and fatigue, he says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x